Reponex has developed and formulated a medicinal product containing GM-CSF and two antibiotics for instillation into the peritoneal cavity at operation
Reponex’s drug combination is expected to have a relevant therapeutic effect to prevent and treat peritonitis resulting from perforation of the gastrointestinal tract, e.g. perforated appendix or after bowel surgery and thereby significantly reduce hospitalization for the benefit of the patients and costs.
After a successful clinical phase II acceptability and safety study, the second clinical phase II study on perforated appendix in collaboration with Herlev Hospital is in the final stage.
- Primary peritonitis (spontaneous peritoneal infection with microorganisms penetrating from the bowel)
- Secondary peritonitis (peritoneal infection with microorganisms escaping from a perforated bowel)
- Peritonitis associated with peritoneal dialysis (peritoneal infection due to an infected dialysis catheter)
- Tertiary peritonitis (low-grade recurrent or persistent peritoneal infection following the above)
It is estimated that there are about 200,000 cases per year in the USA and Europe of the above categories 2 and 3, which make up more than 90% of all cases of peritonitis. No accurate figures are available.